Business Context and Reporting Period
Puma Biotechnology, Inc. filed this Form 8-K on May 9, 2018, reporting events occurring on May 8, 2018. The filing primarily addresses the entry into a material definitive agreement regarding a credit facility amendment and references the company's financial results for the first quarter ended March 31, 2018.
Key Financial Metrics and Debt Structure
The filing details a significant restructuring of the company's debt obligations rather than providing specific revenue or profit figures for the quarter.
- Total Credit Facility: $155 million in term loans.
- Term Loan A: $125 million available immediately on May 8, 2018, used in part to repay the original term loan.
- Term Loan B: $30 million available at the company's option between September 30, 2018, and December 31, 2018, contingent on achieving a specified minimum revenue milestone.
- Interest Rate: The greater of 8.25% or the prime rate plus 3.5%.
- Repayment Terms: Interest-only payments until July 1, 2020, followed by principal and interest payments. Full maturity is May 1, 2023.
- Final Payment: A fee equal to 7.5% of the original principal amount of funded Term Loans is due upon repayment.
- Upfront Fees: $4,162,500 paid on the amendment date.
- Collateral: Substantially all personal property (excluding intellectual property) and 65% of the capital stock of subsidiary Puma Biotechnology Ltd.
The filing text does not provide specific values for revenue, net income, operating cash flow, or margins for the first quarter of 2018, as these are contained in the referenced press release (Exhibit 99.1) which is not included in the source text.
Material Changes and Covenants
The primary material change is the amendment of the loan and security agreement with Silicon Valley Bank and Oxford Finance LLC. Key covenants include:
- Revenue Covenants: The company must achieve product revenue on a trailing 3-month basis that is at least 70% of its board-approved 2018 fiscal year target and 50% of its 2019 fiscal year target.
- Negative Covenants: Restrictions on incurring additional indebtedness, mergers, acquisitions, paying dividends, and selling assets.
- Prepayment Penalties: Fees of 3.0%, 2.0%, or 1.0% apply depending on whether prepayment occurs within the first, second, or subsequent years prior to maturity.
Outlook, Risks, and Contingencies
The company's ability to access the remaining $30 million of the credit facility is contingent on meeting revenue milestones. The agreement includes standard events of default, such as failure to pay principal or interest, insolvency, or material adverse changes. Upon an event of default, the interest rate increases by 5.0%, and lenders may exercise remedies against collateral, including the company's cash.
Investor Verification Checklist
- Verify the specific Q1 2018 revenue and net loss figures in the referenced press release (Exhibit 99.1).
- Confirm the company's current cash position and liquidity status post-transaction.
- Review the board-approved revenue projections for 2018 and 2019 to assess the feasibility of the 70% and 50% covenant thresholds.
- Monitor the company's ability to meet the revenue milestone required to draw the $30 million Term Loan B.
- Assess the impact of the 7.5% final payment fee and interest-only period on long-term cash flow requirements.